Investor Presentation

Biologic Activity of Lenabasum in Patients with Targeted Diseases. 16 X Systemic Sclerosis Improvement/stability in skin inflammation Placebo N = 13 Lenabasum N = 23 69% 46% Placebo 0.6 15% Worsened Unchanged Improvement/stability in skin fibrosis. Improved Lenabasum 0.4- 0.2- 16% 0.0 15% 39% Drug, base Fibronectin FDR=0.0064 P = 0.008 Fisher's exact test two-sided Decreased expression of relevant genes Drug, post PBO, base P = 0.049 Fisher's exact test two-sided FDR=0.6792 PBO, base Expression values 0.8- 0.6- 0.4- 0.2- 0.0 -0.2 48% Drug, base 14% Drug, post 9% 48% Thrombospondin 1 FDR=0.0216 PBO, base FDR=0.0724 38% PBO, base 43% Dermatomyositis Co-localization of CD4, CB2, IFNy staining in skin Decrease in CD4 T cells and Type I IFN signature CD4 Area (%) 15 FN-Beta Area (%) 20 Lenabasum * Visit 1 Visit 6 Lenabasum Visit 1 Visit 6 Placebo ns 1]] Visit 1 Visit 6 Placebo Visit 1 ns Type I IFN Signature Visit 6 50 IFN-Gamma mRNA 40 Reduction in IFNB and IFNY Lenabasum MA Visit 1 Visit 6 Lenabasum Visit 1 Visit 6 Visit 1 Visit 1 Placebo ns Visit 6 Placebo ns Visit 6 Cystic Fibrosis Reduction in inflammatory markers in lung sputum p = 0.053 p = 0.089 -2.5 Reduction with lenabasum 20 mg BID compared to placebo (Log10) -2 Lenabasum -1.5 -1 -1.49 -1.34 -0.70 p = 0.061 P = 0.033 -0.5 -0.61 p = 0.037 Least squares mean difference from placebo (SE), Log 10 -0.23 -0.19 -0.19 0 Neutrophils, cells/ml Eosinophils, cells/ml Lymphocytes, cells/ml Macrophages, cells/ml Neutrophil elastase, mcg/ml IL-8, pg/mL IgG, mg/dl

View entire presentation